PathoGenesis IPO will support Phase III inhaled tobramycin trials.
Executive Summary
PATHOGENESIS IPO WIL FUND INHALED TOBRAMYCIN DEVELOPMENT as well as other research programs at the Seattle-based start-up firm. PathoGenesis began Phase III clinical trials in July of PA-1005 to treat chronic pseudomonal bacterial lung infections in cystic fibrosis patients. PA-1005 is "a novel, stable, premixed formulation of the antibiotic tobramycin for delivery by inhalation," a Sept. 20 initial public offering prospectus explains.